PL89025B1 - - Google Patents

Download PDF

Info

Publication number: PL89025B1
Authority: PL; Poland
Prior art keywords: weight; solution; parts; nitrophenyl; sublingually
Prior art date: 1972-02-29

Application number

PL15741472A

Other languages

English (en)

Polish (pl)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1972-02-29

Filing date

1972-08-23

Publication date

1976-10-30

1972-08-23 Application filed filed Critical

1976-10-30 Publication of PL89025B1 publication Critical patent/PL89025B1/pl

Links

239000002775 capsule Substances 0.000 claims description 15
239000000126 substance Substances 0.000 claims description 15
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
238000000034 method Methods 0.000 claims description 10
229920000159 gelatin Polymers 0.000 claims description 9
235000019322 gelatine Nutrition 0.000 claims description 9
239000013543 active substance Substances 0.000 claims description 8
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
235000011187 glycerol Nutrition 0.000 claims description 6
239000004408 titanium dioxide Substances 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
239000001828 Gelatine Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 4
210000004351 coronary vessel Anatomy 0.000 claims description 4
238000011049 filling Methods 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 3
229920001515 polyalkylene glycol Polymers 0.000 claims description 3
235000013305 food Nutrition 0.000 claims description 2
230000000087 stabilizing effect Effects 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
239000006224 matting agent Substances 0.000 claims 1
125000006501 nitrophenyl group Chemical group 0.000 claims 1
239000003814 drug Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 11
206010002383 Angina Pectoris Diseases 0.000 description 7
108010010803 Gelatin Proteins 0.000 description 5
OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
-1 polyethylene Polymers 0.000 description 5
239000000975 dye Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000013980 iron oxide Nutrition 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
229920000151 polyglycol Polymers 0.000 description 3
239000010695 polyglycol Substances 0.000 description 3
241000416162 Astragalus gummifer Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
240000000467 Carum carvi Species 0.000 description 1
235000005747 Carum carvi Nutrition 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
240000006927 Foeniculum vulgare Species 0.000 description 1
235000004204 Foeniculum vulgare Nutrition 0.000 description 1
241001051053 Garcinia cowa Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004378 Glycyrrhizin Substances 0.000 description 1
235000019501 Lemon oil Nutrition 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
235000019892 Stellar Nutrition 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
229960004050 aminobenzoic acid Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-N aniline-p-carboxylic acid Natural products NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
239000010617 anise oil Substances 0.000 description 1
235000019568 aromas Nutrition 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
229940067573 brown iron oxide Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
235000020960 dehydroascorbic acid Nutrition 0.000 description 1
239000011615 dehydroascorbic acid Substances 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000989 food dye Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
238000005242 forging Methods 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
229960004949 glycyrrhizic acid Drugs 0.000 description 1
UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
235000019410 glycyrrhizin Nutrition 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000001145 hydrido group Chemical group *[H] 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
239000010501 lemon oil Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
238000006303 photolysis reaction Methods 0.000 description 1
230000015843 photosynthesis, light reaction Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
AZLXCBPKSXFMET-UHFFFAOYSA-M sodium 4-[(4-sulfophenyl)diazenyl]naphthalen-1-olate Chemical compound [Na+].C12=CC=CC=C2C(O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 AZLXCBPKSXFMET-UHFFFAOYSA-M 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000004173 sunset yellow FCF Substances 0.000 description 1
235000012751 sunset yellow FCF Nutrition 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)

PL15741472A 1972-02-29 1972-08-23 PL89025B1 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19722209526 DE2209526C3 (de)	1972-02-29	1972-02-29	Coronartherapeutlkum in Form von Gelatine-BeiBkapseln

Publications (1)

Publication Number	Publication Date
PL89025B1 true PL89025B1 (cs)	1976-10-30

Family

ID=5837426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15741472A PL89025B1 (cs)	1972-02-29	1972-08-23

Country Status (4)

Country	Link
AT (1)	AT328073B (cs)
CS (1)	CS199202B2 (cs)
DE (1)	DE2209526C3 (cs)
PL (1)	PL89025B1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3307353C2 (de) *	1983-03-02	1985-01-31	R.P. Scherer GmbH, 6930 Eberbach	Polyethylenglykolhaltige Weichgelatinekapsel und Verfahren zu ihrer Herstellung
US4486412A (en) *	1983-03-15	1984-12-04	Pharmacaps, Inc.	Encapsulated antacid dispersions
DE3438830A1 (de) *	1984-10-23	1986-04-30	Rentschler Arzneimittel	Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3526546A1 (de) *	1985-07-25	1987-01-29	Scherer Gmbh R P	Lichtbestaendige opakisierte gelatinekapseln und verfahren zur herstellung derselben
DE3738236A1 (de) *	1987-11-11	1989-05-24	Euro Celtique Sa	Beisskapsel

1972
- 1972-02-29 DE DE19722209526 patent/DE2209526C3/de not_active Expired
- 1972-08-08 CS CS553172A patent/CS199202B2/cs unknown
- 1972-08-22 AT AT723072A patent/AT328073B/de not_active IP Right Cessation
- 1972-08-23 PL PL15741472A patent/PL89025B1/pl unknown

Also Published As

Publication number	Publication date
DE2209526B2 (de)	1979-06-28
ATA723072A (de)	1975-05-15
DE2209526A1 (de)	1973-09-06
DE2209526C3 (de)	1980-02-28
AT328073B (de)	1976-03-10
CS199202B2 (en)	1980-07-31

Publication	Publication Date	Title
US3784684A (en)	1974-01-08	Coronary dilator in a pharmaceutical dosage unit form
US4842859A (en)	1989-06-27	Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US5397574A (en)	1995-03-14	Controlled release potassium dosage form
JPH072654A (ja)	1995-01-06	吸入によるタウリン投与装置
SE8402549L (sv)	1984-05-11	Substituerade moranolinderivat
Morrison et al.	1960	Vitamin absorption studies: I. Factors influencing the excretion of oral test doses of thiamine and riboflavin by human subjects
US5108750A (en)	1992-04-28	Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
SE8300577D0 (sv)	1983-02-03	Overdrag som tillforsekrar reglerad avgivning av akriva bestandsdelar fran biologiskt aktiva blandningar, i synnerhet farmaceutiska beredningar, jemte sett att framstella biologiskt aktiva blandningar med reglerad ....
DE69011618T2 (de)	1994-12-15	Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
PL89025B1 (cs)	1976-10-30
JPS58134033A (ja)	1983-08-10	医薬組成物
Stolk et al.	1980	Serum levels of 8‐methoxypsoralen: difference between two oral methods of administration
Bablenis et al.	1989	Clozapine: A novel antipsychotic agent
EP0127297B1 (en)	1989-08-23	Vitamin composition with enhanced bioavailability and method of administering same
DE69515573T2 (de)	2000-11-02	Schneidvorrichtung für ein Schneidgerät wie einen Mäher oder einen Heckenschneider
US4906471A (en)	1990-03-06	Pharmaceutical composition for the reducing both hyperlipidemia and platelet-aggregation (PHP)
JPS60500866A (ja)	1985-06-06	抗「すい」臓炎症作用を有する医薬組成物
JPH0515691B2 (cs)	1993-03-02
IE38614B1 (en)	1978-04-26	Orally administrable corticosteroid preparations
US3193461A (en)	1965-07-06	Correcting blood changes with niacin, vitamin a, and riboflavin
JPS6137731A (ja)	1986-02-22	グアバ葉エキスを有効成分とする経口糖尿病薬
CN101491519B (zh)	2011-09-28	一种银杏内酯注射剂及其制备方法
Jonkman et al.	1977	Variations in the bioavailability of thiazinamium methylsulfate
DE69717775T2 (de)	2003-06-12	Kapseln enthaltend Diclofenac oder dessen Salze in Lösung
PT94823A (pt)	1991-04-18	Novo processo de controle da biodisponibilidade de um medicamento oral